Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2007
11/28/2007CN100351270C Antibacterial peptide of brown-spotted torrential frog, its gene and application in drug preparation
11/28/2007CN100351267C Human urine anti-tumor (antibacterial) peptide, its preparation and use
11/28/2007CN100351259C Sulfur-containing phospholipid derivatives
11/28/2007CN100351255C Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic
11/28/2007CN100351253C Pyrrolo [2,3-d] pyrimidine compounds as immunosuppressive agents
11/28/2007CN100351251C Indolylmaleimide derivatives
11/28/2007CN100351249C Quinolinone derivatives as tyrosine kinase inhibitors
11/28/2007CN100351245C Oxa- and thiadiazoles and their use as metalloproteinase inhibitors
11/28/2007CN100351244C Bis-aromatic alkanols
11/28/2007CN100351242C Processes and intermediates for preparing anti-cancer compounds
11/28/2007CN100351241C Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis (2-methoxyethoxy)-4-quinazolinamine hydrochloride, method of production and pharmaceutical uses thereof
11/28/2007CN100351237C Novel hererocyclic compound and preparation thereof and medicine composition containing same and use thereof in medicine
11/28/2007CN100351235C 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composi
11/28/2007CN100351234C Bis-heterocyclic compounds with antitumour and chemosensitising activity
11/28/2007CN100351233C Fullerene derivative of E-isomer
11/28/2007CN100350981C Radioactive therapeutic Liposomes
11/28/2007CN100350980C Method for preparing 131I marker GM-CSF protein for treating leukemia
11/28/2007CN100350975C Anticarcinogen composition
11/28/2007CN100350974C Anticarcinogen composition
11/28/2007CN100350973C Drug composition for curing disease produced from IL-6
11/28/2007CN100350950C Wuzishan Chinese medicines for cancer pains
11/28/2007CN100350946C Chinese medicine for treating neoplasm
11/28/2007CN100350902C Hypoglycemic agent, liver protecting agent and anticancer agent containing lignans originating in hongdoushan
11/27/2007US7301028 Mitotic kinesin inhibitors
11/27/2007US7301023 Immunosuppressants; grafting of organs; rheumatic diseases
11/27/2007US7301022 N-(2-(6-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-ylamino)pyrimidin-4-yl)-5-(trifluoromethyl)phenyl)-1-isopropylpyrrolidine-2-carboxamide hydrochloride; antiinflammatory agents, analgesics, antiarthritic agents, antiulcer agents
11/27/2007US7301005 Immunomodulatory peptides derived from heat shock proteins and uses thereof
11/27/2007US7300952 NF-κb inhibitors
11/27/2007US7300944 Alzheimer's disease, bipolar disorder, diabetes, dementia, stroke, schizophrenia, depression, hair loss, cancer
11/27/2007US7300943 Pyrazolo[3,4-b]pyridin-6-ones which are inhibitors of cyclin-dependent protein kinases and glycogen synthase kinase; diabetes, dementia, Alzheimer's disease, stroke, schizophrenia, alopecia, and cancer; antiasthmatics, angiogenesis inhibitors; antiproliferative, neuroprotective and neuroleptic agents
11/27/2007US7300942 For therapy of a fungal infection
11/27/2007US7300935 Gonadotropin-releasing hormone antagonistic activity, therapy of prostatic cancer, endometriosis, precocious puberty; N-(4-(1-(2,6-difluorobenzyl)-5-(((2-ethoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea
11/27/2007US7300933 Diazabicyclic biaryl derivatives
11/27/2007US7300930 Therapeutic acridone and acridine compounds
11/27/2007US7300925 treating psoriasis with e.g. 19-nor-2beta-ethyl-1alpha,25-dihydroxyvitamin D3
11/27/2007US7300922 Enhancing or inhibiting the biological activity of nucleic acid ligands by administrating a modulator, to change the binding of the nucleic acid ligand for its target or degrading or cleaving
11/27/2007US7300765 SC6 for diagnosis of cancers
11/27/2007US7300655 Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof
11/27/2007US7300652 Contacting cell expressing kidney injury-molecule-1 (KIM-1) cell surface polypeptide with an effective amount of an isolated antibody or antigen-binding-fragment thereof that binds to the extracellular domain of the human KIM-1 polypeptide
11/27/2007US7300650 Reovirus for the treatment of neoplasia
11/27/2007CA2432196C Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors
11/27/2007CA2391333C Sustained release formulation of a peptide and a copolymer
11/27/2007CA2379695C Compounds for modulating the rage receptor
11/27/2007CA2358998C Substituted bicyclic derivatives useful as anticancer agents
11/27/2007CA2290557C Use of 4-substituted tetrahydropyridines for making medicines acting on tgf-.beta.1
11/27/2007CA2271683C Coated particles, methods of making and using
11/22/2007WO2007134245A2 Elastin-like polymer delivery vehicles
11/22/2007WO2007134203A2 Anticancer treatments with a combination of docetaxel and ecteinascidin
11/22/2007WO2007133809A2 Separable sheath and method of use
11/22/2007WO2007133622A2 Selective inhibitors of rock protein kinase and uses thereof
11/22/2007WO2007133112A1 Noscapine derivatives (variants), combinatory and focused library, pharmaceutical composition, methods for the production (variants) and the use thereof
11/22/2007WO2007132948A1 Cinnamoyl compound and use thereof
11/22/2007WO2007132945A1 Cinnamoyl compound and use thereof
11/22/2007WO2007132893A1 Suppressor of expression of mcp-1, and ameliorating agent for inflammatory disease, pharmaceutical, supplement, food, beverage or food additive using the suppressor
11/22/2007WO2007132882A1 Pharmaceutical composition for treating or preventing hcv infection
11/22/2007WO2007132867A1 Prophylactic and therapeutic agent for cancer
11/22/2007WO2007132852A1 Poorly-water-soluble pharmaceutical agent
11/22/2007WO2007132846A1 Compound having acidic group which may be protected, and use thereof
11/22/2007WO2007132496A1 Dioxaspiroketal derivatives, process for their preparation and uses thereof
11/22/2007WO2007132308A1 Triazolopyrazine derivatives useful as anti-cancer agents
11/22/2007WO2007132307A1 Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
11/22/2007WO2007132234A1 Pharmaceutical compositions comprising 5-aminolevulinic acid
11/22/2007WO2007132228A1 Combination of cndac with a 2-substituted-4-heter0aryl-pyrimidine amine and use thereof in the treatment of a proliferative disorder
11/22/2007WO2007132227A1 Maleate co-crystal of azd1152
11/22/2007WO2007132220A1 Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
11/22/2007WO2007132215A1 Combination therapy for the treatment of cancer
11/22/2007WO2007132190A1 Composition for the treatment of resistant cancers comprising oridonin
11/22/2007WO2007132171A1 Pharmaceutical compounds
11/22/2007WO2007132037A1 Method for synthesizing thymosins
11/22/2007WO2007132010A1 2, 4 -diamino pyrimidines as cell cycle kinase inhibitors
11/22/2007WO2007131767A2 Novel actives against prostate carcinoma
11/22/2007WO2007131737A2 Medication against breast cancer and related diseases
11/22/2007WO2007131736A2 Use of 4, 17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
11/22/2007WO2007131689A2 Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitor
11/22/2007WO2007131601A1 A process for the preparation of a taxane derivative
11/22/2007WO2007131366A1 Iap bir domain binding compounds
11/22/2007WO2007131365A1 Treatment of neoplastic disorders using a farnesyl dibenzodiazepinone administered by continuous intravenous infusion
11/22/2007WO2007109330A3 S1p receptor modulating compounds
11/22/2007WO2007107161A8 Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis
11/22/2007WO2007106436A3 Photoactive compounds and compositions and uses thereof
11/22/2007WO2007105989A3 1-oxo-3-(1h-indole)-3-il-1,2,3,4-tetrahydroisoxynolines, methods for the production thereof, combinatoric library and focused library
11/22/2007WO2007095495A3 Benzodiazepine gcnf modulators for stem cell modulation
11/22/2007WO2007084670A3 Specific therapy using integrin ligands for treating cancer
11/22/2007WO2007081091A8 Rhodandse derivarives, a process for the preparation thereof and pharmaceutical composition containing the same
11/22/2007WO2007071777A3 Immuno-rna-constructs
11/22/2007WO2007065023A3 Processes for obtaining lignan extracts and compositions containing the lignan extracts
11/22/2007WO2007033959A3 Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
11/22/2007WO2007022412A3 Combination therapy for preventing angiogenesis comprising a inhibitor ofhif-1 and a further anti-angiogenic agent
11/22/2007WO2006130532A3 Treatment of liver diseases in which iron plays a role in pathogenesis
11/22/2007WO2006057886A8 2-METHYLENE-19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND ITS USES
11/22/2007WO2005117543A3 N-sulfonylcarboximidamide apoptosis promoters
11/22/2007WO2000018212A8 Platelet-derived growth factor c, dna coding therefor, and uses thereof
11/22/2007US20070270577 Genetic engineering; obtain cells, transform with vector containing protein, express vector, recover protein; contacting preparations of a recombinant protein with a reduction/oxidation coupling reagent for a time sufficient to increase the relative proportion of a desired configurational isomer
11/22/2007US20070270575 Protein showing enhanced expression in cancer cells
11/22/2007US20070270505 Gefitinib Sensitivity-Related Gene Expression and Products and Methods Related Thereto
11/22/2007US20070270504 Identification of Therapeutic Agents Using Genetic Fingerprinting
11/22/2007US20070270488 Treatment and Assays
11/22/2007US20070270485 Byrostatin analogues, synthetic methods and uses
11/22/2007US20070270476 Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
11/22/2007US20070270465 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl) piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
1 ... 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 ... 2211